Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Fiche publication
Date publication
septembre 2020
Journal
Expert review of clinical immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
After patents' expiration of biological originators, several biosimilars of infliximab and adalimumab have been authorized. The approval is based on data extrapolated from other indications for which the originator has been previously tested. Despite rigorous approval processes by regulatory entities, physicians' and patients' knowledge about biosimilars is limited and some concerns about their use persist.
Mots clés
biosimilars, cost-saving, inflammatory bowel diseases, nocebo effect, non-medical switching, switching
Référence
Expert Rev Clin Immunol. 2020 Sep 21;: